Vanguard DAP
Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine, Modified Live Virus, dogs. Preservative: Gentamicin.
VANGUARD� DA2P
Zoetis
Canine Distemper-Adenovirus Type 2-Parainfluenza Vaccine
Modified Live Virus
For use in dogs only
PRODUCT DESCRIPTION: Vanguard DA2P is for vaccination of healthy dogs as an aid in preventing canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), and canine parainfluenza caused by canine parainfluenza (CPI) virus. Vanguard DA2P contains attenuated strains of CD virus, CAV-2, and CPI virus propagated on an established canine cell line and freeze-dried to preserve stability.
SAFETY AND EFFICACY: Safety of Vanguard DA2P was confirmed in laboratory and field tests.1 In more than 15,000 vaccinated dogs, no significant postvaccination reactions attributable to the vaccine were reported. These findings are particularly important since adverse side effects sometimes follow vaccination with modified live ICH vaccine. After vaccination with ICH vaccine, persistent kidney infections may occur, causing virus shedding in urine. Uveitis and corneal opacity also are occasionally observed 1-2 weeks after vaccination.2 Vaccination with the CAV-2 fraction in Vanguard DA2P, however, produced no such lesions. Challenge virus was not recovered from vaccinated dogs, and was not isolated from tissues taken at necropsy. Ocular lesions were not observed in any of 172 dogs inoculated intravenously with multiple doses of CAV-2 vaccine virus, while intravenous inoculation of 32 dogs with ICH vaccine produced ocular lesions in 22%. Additionally, the strain of CAV-2 in this product has been shown free of oncogenic properties characteristic of canine adenovirus.
DIRECTIONS:
1. General Directions: Vaccination of healthy dogs is recommended. Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 1 mL subcutaneously or intramuscularly.
2. Primary Vaccination: Healthy dogs should receive 2 doses administered 3-4 weeks apart. If dogs are vaccinated before the age of 4 months, they should be revaccinated upon reaching 4 months of age. (Maternal antibodies may interfere with development of an adequate immune response in puppies less than 4 months old.)
3. Revaccination: Annual revaccination with a single dose is recommended, although, as recommended by the American Veterinary Medical Association and its Council on Biologic and Therapeutic Agents, the attending veterinarian should determine the frequency of revaccination based on the animal's lifestyle and risk of exposure.6
PRECAUTIONS:
1. Store at 2�-7�C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.
2. Use entire contents when first opened.
3. Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.
4. Burn containers and all unused contents.
5. Contains gentamicin as preservative.
6. Vaccination of pregnant bitches should be avoided.
7. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.
8. This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.